BioWorld Science

Feb. 2, 2009

View Archived Issues

New renin inhibitors disclosed in joint patent from GSK and Vitae

Read More

Kv1 potassium channel inhibitors with anxiolytic properties synthesized at Lectus Therapeutics

Read More

Novel anti-VEGF antibodies in development at Domantis

Read More

Bristol-Myers Squibb imparts glucokinase activators for type 2 diabetes

Read More

Betagenon initiates U.K. investigational medicinal product-enabling studies for BG-8702

Read More

Genzyme profiles pipeline progression

Read More

Novel sodium channel blockers with analgesic activity developed at AstraZeneca

Read More

GSK claims new CGRP receptor antagonists useful for treating migraine and cluster headache

Read More

New HIV RT inhibitors jointly developed by Gilead & Korea Research Institute of Chemical Technology

Read More

FDA requests Pro-Pharmaceuticals to conduct phase III trial of Davanat in colorectal cancer

Read More

BioMS Medical reports results of exploratory phase II dirucotide trial in MS

Read More

Revotar Biopharmaceuticals starts phase II bimosiamose 5% cream trial

Read More

Supernus initiates phase IIa SPN-810 trial in conduct disorder

Read More

NeuroSearch and GSK extend and expand drug discovery alliance

Read More

Small molecule blocks sonic hedgehog signaling

Read More

Bortezomib effective in treating renal transplant rejection

Read More

Santarus submits NDA for addition to Zegerid product portfolio

Read More

Progen directors unanimously recommend proposed merger with Avexa

Read More

GlaxoSmithKline and Genmab submit Arzerra BLA to FDA

Read More

Patient recruitment resumes in FibroGen's phase II oral FG-4592 trial

Read More

Pfizer discontinues phase III axitinib study

Read More

Shionogi enters into licensing agreement on peptide vaccines with OncoTherapy

Read More

EpiCept receives FDA permission to file NDA for Ceplene in AML

Read More

FDA approves Kapidex for the treatment of GERD and erosive esophagitis

Read More